Clinical Trial

A First-in-Human Single and Multiple Ascending Dose Study of MT-251

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Doses of MT-251 in Healthy Participants
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-02-13; most recent amendment 2026-02-23.
Trial Details
NCT Number NCT07423299
Lead Sponsor Mirador Therapeutics, Inc.
Conditions Healthy Volunteers
Enrollment 70 participants
Start Date 2026-01-23
Primary Completion 2027-03-08 (estimated)
Study Completion 2027-03-08 (estimated)
Updated on ClinicalTrials.gov 2026-02-25